Successful venom immunotherapy in a child with anaphylaxis to Hymenoptera skin testing
Omalizumab has been used during venom immunotherapy primarily for high-risk adult patients. We report a similar approach in a child with anaphylaxis in response to Hymenoptera skin testing who successfully tolerated modified rush venom immunotherapy with concurrent use of omalizumab.
Authors
- Ana Dioun Broyles
- Ellen Conroy (ORCID: https://orcid.org/0009-0009-5765-1078)
- Simon Bailey (ORCID: https://orcid.org/0000-0001-9348-5497)
- J. David Garrett
Institutions
- Boston Children's Hospital (US)
- Harvard University (US)
- Amherst College (US)
- Associates Research (UG)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.jacig.2025.100619
- Primary Topic
- Food Allergy and Anaphylaxis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00